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Background – Coronary artery disease (CAD) is a multifactorial condition with both genetic 2 
and exogenous causes. The contribution of tissue specific functional networks to the 3 
development of atherosclerosis remains largely unclear. The aim of this study was to identify 4 
and characterise central regulators and networks leading to atherosclerosis.  5 
Methods – Based on several hundred genes known to affect atherosclerosis risk in mouse (as 6 
demonstrated in knock-out models) and human (as shown by genome-wide association studies 7 
(GWAS)) liver gene regulatory networks were modeled. The hierarchical order and regulatory 8 
directions of genes within the network were based on Bayesian prediction models as well as 9 
experimental studies including chromatin immunoprecipitation DNA-Sequencing (ChIP-Seq), 10 
ChIP mass spectrometry (ChIP-MS), overexpression, siRNA knockdown in mouse and human 11 
liver cells, and knockout mouse experiments. Bioinformatics and correlation analyses were 12 
used to clarify associations between central genes and CAD phenotypes in both human and 13 
mouse.  14 
Results – The transcription factor MAFF interacted as a key driver of a liver network with three 15 
human genes at CAD GWAS loci and eleven atherosclerotic murine genes. Most importantly, 16 
expression levels of the low-density lipoprotein receptor (LDLR) gene correlated with MAFF 17 
in 600 CAD patients undergoing bypass surgery (STARNET) and a hybrid mouse diversity 18 
panel involving 105 different inbred mouse strains. Molecular mechanisms of MAFF were 19 
tested under non-inflammatory conditions showing a positive correlation between MAFF and 20 
LDLR in vitro and in vivo. Interestingly, after LPS stimulation (inflammatory conditions) an 21 
inverse correlation between MAFF and LDLR in vitro and in vivo was observed. ChIP-MS 22 




stimulation with respective heterodimers binding at the MAF recognition element (MARE) of 1 
the LDLR promoter to transcriptionally downregulate LDLR expression.  2 
Conclusion – The transcription factor MAFF was identified as a novel central regulator of an 3 
atherosclerosis/CAD relevant liver network. MAFF triggered context specific expression of 4 
LDLR and other genes known to affect CAD risk. Our results suggest that MAFF is a missing 5 
link between inflammation, lipid and lipoprotein metabolism and a possible treatment target. 6 
Keywords 7 
Atherosclerosis, BACH1, coronary artery disease, inflammation, key driver analysis, LDLR, 8 




Translational Perspective  1 
What is new? 2 
• Our study identified the transcription factor MAFF as key driver gene in a liver-3 
specific network involving several genes with established, genome-wide significant 4 
association to coronary artery disease (CAD).  5 
• MAFF regulated context-specifically expression of LDLR in experimental model 6 
systems and human individuals. 7 
• MAFF induced LDLR expression under non-inflammatory conditions. After LPS 8 
stimulation MAFF downregulated LDLR expression via heterodimerisation with 9 
BACH1 and binding at the maf-recognition element (MARE) – also known as stress-10 
responsive element – in the promoter of LDLR. 11 
What are the clinical implications? 12 
• Cholesterol metabolism and inflammation represent two major causes of CAD. Here 13 
we identified a transcriptional regulator (MAFF) to differentially affect the major 14 
determinant of cholesterol levels (LDLR) dependent on the inflammatory state. 15 
• Further studies of the transcription factor MAFF, its interaction partners and 16 
downstream cascades might generate new therapeutic targets to treat 17 





Coronary artery disease (CAD), a globally leading cause of death,1, 2 is brought about by 2 
atherosclerosis of the epicardial arteries, which is prompted by a multifactorial interplay of 3 
genetic and lifestyle factors.3 From a functional point of view, the mechanisms which result in 4 
CAD can be grouped into different pathways or networks.4-7 A systematic analysis of genes 5 
identified by genome-wide association studies (GWAS) of CAD patients and genetic mouse 6 
models of atherosclerosis revealed a strong concordance of relevant networks and pathways for 7 
atherosclerosis between the two species.8 However, characterization and regulation of these 8 
functional networks is far from being complete.9 Central mechanisms for atherosclerosis are 9 
the disturbance of cholesterol metabolism and inflammation, which – like CAD – have 10 
multifactorial etiologies.10-12 Clinical as well as epidemiological trials and Mendelian 11 
randomization studies confirmed that elevation of plasma cholesterol and increased 12 
inflammation promote the progression of atherosclerosis and CAD13-16, whereas reduction of 13 
plasma cholesterol levels and inflammatory processes lowered significantly the subsequent risk 14 
of cardiovascular events.10, 17-19 Both, cholesterol metabolism and inflammatory responses are 15 
largely orchestrated in the liver. Therefore, the analysis focused on hepatic tissue to further 16 
elucidate regulatory gene networks involved in atherosclerosis.  17 
 18 
Methods 19 
Data used in this study are available in persistent repositories. Human data from STARNET are 20 
accessible through the Database of Genotypes and Phenotypes (dbGAP). Mouse data from 21 
HMDP are accessible through the Mouse Phenome Database (MPD). All experimental data 22 
supporting the findings of this study can be requested from qualified researchers at the German 23 




methods section is provided in the supplement section (Expanded Methods). Human and 1 
mouse candidate genes were retrieved from the literature.8, 20-30 Gene-gene relations of 2 
atherosclerotic genes were retrieved utilising Bayesian gene regulatory networks derived from 3 
previous expression analyses on human and mouse tissues as described.31-36 The key driver 4 
analysis (KDA) was based on an established algorithm to identify central regulators of 5 
atherosclerosis relevant networks.31, 37-40 ChIP-Seq experiments of MAFF on human HepG2 6 
cells were performed as described.41-44 Binding capacities of MAFF and heterodimerisation 7 
partners were confirmed using ChIP-Seq data. siRNA experiments targeting liver genes were 8 
performed in cultured AML12 murine and Hep3b human liver cells. Maff overexpression 9 
experiments were performed in AML12 cells. ChIP-MS was performed to identify MAFF 10 
binding partners. Molecular docking of heterodimerisation partners was assessed based on 11 
lowest free energy.45-48 The STARNET study was conducted in accordance with the provisions 12 
of the Declaration of Helsinki and the International Conference on Harmonization Good 13 
Clinical Practice guidelines. The protocol was approved by an independent ethics committee 14 
and all patients provided written informed consent. All animal studies in mice followed the 15 
guidelines of the Animal Care and Use Committees of the University of California Los Angeles. 16 
The approach is graphically summarised in Figure 1.  17 
 18 
Results 19 
Bioinformatics identification of the MAFF network 20 
The bioinformatics approach was based on a comprehensive search for mouse genes that have 21 
been previously found to affect the manifestation of atherosclerosis in genetically engineered 22 
mouse models as well as human chromosomal loci significantly associated with CAD in GWAS 23 




CAD GWAS candidate genes (Supplemental Table 1) and 827 mouse atherosclerosis genes 1 
(Supplemental Table 2) were used to model gene regulatory networks using a key driver 2 
analysis.49 Liver Bayesian network models composed from multiple published genetic and gene 3 
expression datasets were constructed to retrieve gene-gene regulatory relationships in each 4 
dataset,31-36 followed by summarising the individual liver networks into a union liver Bayesian 5 
network (Expanded Methods). The mouse atherosclerosis genes and human CAD GWAS 6 
genes were then mapped separately to the liver Bayesian network model to retrieve subnetworks 7 
(specific parts of the global Bayesian liver network) of disease genes and to predict key 8 
regulatory genes in these subnetworks. Several subnetworks enriched for known atherosclerosis 9 
or CAD associated genes were identified. Figure 2 displays the interconnected top 10 liver 10 
subnetworks containing mouse atherosclerosis or human CAD genes. Table 1 lists these 11 
subnetworks in mouse and human ranked by fold enrichment of disease genes in each 12 
subnetwork. Based on mouse atherosclerosis genes, the top five key driver genes of the 13 
regulatory networks were Maff, Il1b, Ccl7, Atf3 and Cxcl10. With the exception of Maff these 14 
genes have already been shown to have significant effects on atherosclerosis in mouse models, 15 
which may serve as positive control for this approach.50-53 Regarding the human CAD genes, 16 
the top ranked key driver gene ALDH2 is known to reside at a CAD GWAS locus. The key 17 
driver SERPINE1, which is also part of the MAFF network, shares several atherosclerosis 18 
relevant genes with MAFF. 19 
The top ranked liver subnetwork, over-represented with both mouse atherosclerosis and human 20 
CAD candidate genes, was predicted to be orchestrated by MAFF/Maff, which interacts with 21 
24 atherosclerosis related genes. A number of these genes are known to be associated with lipid 22 
metabolism and others with inflammation, and eleven genes (Atf3, Epha2, Gdf15, Ldlr, Nr4a3, 23 




genetically engineered mouse models.53-63 On the human side, the MAFF interacting genes 1 
LDLR, MCL1 and TRIB1 reside at genome-wide significant CAD GWAS loci.  2 
MAFF is a member of the MAF family, which consists of large and small MAF proteins. Large 3 
MAFs possess a transactivation domain and modulate regulatory processes. Small MAFs are 4 
lacking a transactivation domain and are therefore classified as transcriptional repressors.64 5 
MAFF, a small MAF, is a basic region leucine zipper (bZIP)-type transcription factor composed 6 
of a DNA binding domain and a leucine zipper domain necessary for dimerisation. MAFF can 7 
mediate both transcriptional activation or repression by forming heterodimers with other bZIP 8 
transcription factors. But the precise mechanism by which MAFF forms specific dimers, and 9 
therefore induces or represses specific target genes is currently not well established.  10 
 11 
Prediction of regulatory directionality in the MAFF/Maff network 12 
Individual liver Bayesian network models were constructed using multiple genetic and gene 13 
expression datasets from mouse and human studies and combined the networks into one union 14 
liver network (Expanded Methods). As the directionality between two genes in a network 15 
might differ across studies due to different environmental perturbations and physiological states, 16 
the dominant direction that is supported by more datasets was taken as the directionality 17 
between two genes (Figure 2).  18 
Based on this data ATF3, TRIB1, SERPINE1, FOSL2, and ZFP36 were predicted to be upstream 19 
of MAFF, i.e. these genes appear to affect regulation of the transcription factor. All other genes 20 
of interest in the context of atherosclerosis (ARID5B, CLCF1, CREM, CXCL8, DUSP5, EPHA2, 21 




TNFAIP3, TNFRSF12A and TSC22D1) were predicted to be downstream of MAFF and 1 
therefore likely to be regulated by the transcription factor MAFF. 2 
 3 
Confirmation of Maff coexpression with lipid metabolism and inflammation processes in 4 
mouse atherosclerosis models  5 
The Hybrid Mouse Diversity Panel (HMDP) is a set of 105 different inbred mouse strains, 6 
which were studied under different dietary conditions and different genetic backgrounds.65, 66 7 
Ldl and Vldl cholesterol levels increased from chow diet over high-fat diet to the atherogenic 8 
transgenic mice on high-fat diet (26mg/dl vs. 42mg/dl, vs. 92mg/dl; p<0.001). In transgenic 9 
mice inflammation associated factors like Il1b, Il6 and Tnfa were also upregulated.  10 
On regular chow (Pearson’s r=0.30, p=9.88e-07) and high-fat diet (Pearson’s r=0.35, p=1.78e-11 
07) positive correlations between Maff and Ldlr were detected. By contrast, in mice on high-fat 12 
diet with transgenic expression of human APOE-Leiden and cholesteryl ester transfer protein 13 
(CETP), causing increased hyperlipidemia and inflammation, significant inverse correlations 14 
between Maff and Ldlr were observed (Pearson’s r=-0.27, p=4.65e-05). Correlations between 15 
Maff and its network interaction partners are summarised in Supplemental Table 3. Also, 16 
associations between Maff and various molecular and biochemical phenotypes were studied, 17 
showing significant correlations with atherosclerosis related traits under non-inflammatory 18 
conditions (mice on chow and high-fat diet): total cholesterol (Pearson’s r=0.31, p=7.90e-4), 19 
unesterified cholesterol (Pearson’s r=0.38, p=2.22e-3), body weight (Pearson’s r=0.32, 20 
p=1.54e-3); and inflammatory conditions (atherogenic): aortic lesion area (as a measure of 21 
atherosclerotic lesions) (Pearson’s r=-0.37, p=1.34e-3), Il6-levels (element of the 22 
inflammasome axis; Pearson’s r=0.45, p=5.24e-6), Tnfa-levels (as a measure of inflammation; 23 




dendritic cells to the sites of inflammation; Pearson’s r=0.33, p=1.09e-3). Furthermore, the 1 
density of absolute values of Pearson correlation efficient r was assessed between gene pairs of 2 
the Maff network as a parameter of network gene coexpression or connection activity and the 3 
network coexpression activity between HMDP panels (chow vs. high fat vs. atherogenic) was 4 
compared. Overall, significantly increased gene-gene coexpression from chow diet over high-5 
fat diet to the transgenic group was identified (p<0.01) (Supplemental Figure 1). The gradual 6 
elevation of coexpression activity of the Maff network along with the accompanying increases 7 
in cholesterol levels from low-atherogenic to high-atherogenic conditions suggests a context-8 
specific role of Maff in the regulation of the liver gene network and LDL cholesterol.  9 
 10 
Confirmation of MAFF coexpression with CAD and related processes in human liver  11 
To study the effects of MAFF in humans with CAD phenotype data from the Stockholm-Tartu 12 
Atherosclerosis Reverse Network Engineering Task (STARNET) were used. STARNET 13 
provides RNA-sequencing data from different tissues of 600 CAD patients undergoing 14 
coronary artery bypass graft (CABG) surgery. All patients gave written informed consent to 15 
donate tissue samples prior to CABG surgery.9 Based on liver samples in STARNET, a strong 16 
positive correlation between expression levels of MAFF and LDLR (Pearson’s r=0.57, p=4.7e-17 
49) was detected (Figure 3a). Studying the MAFF network expression values, 22 out of the 24 18 
predicted neighbouring genes were found to be significantly correlated to MAFF expression 19 
(Supplemental Table 1).  20 
MAFF expression was also associated with several cardiometabolic traits in the STARNET 21 
database. Importantly, MAFF expression was inversely associated with the SYNTAX-Score I 22 
– a measure of CAD severity (Pearson’s r=-0.1; p<0.01). Weight (Pearson’s r=-0.19; p=4.4e-6) 23 




MAFF expression, whereas MAFF expression was positively correlated with hsCRP (Perason’s 1 
r=0.1; p<0.01). Notably, MAFF expression values were higher in women (p=5.5e-3) (Figure 2 
3b), such that it might be of interest that 9 MAFF interacting genes in Supplemental Table 3 3 
(ATF3, EPHA2, FOXP1, GDF15, SERPINE1, SLC20A1, TGFBI, TNFRSF12A and ZFP36) 4 
have been recognised as sexually dimorphic in mice.34 We note that the phenotypic correlations 5 
between MAFF and phenotypes other than CAD were weak in this human CAD cohort 6 
compared to the genetically defined mouse populations. This could be explained by low 7 
phenotypic variability or medication in the CAD cohort.  8 
Summarising the results from the STARNET cohort, lower levels of MAFF expression were 9 
correlated with I) lower levels of LDLR expression (less capacity to lower circulating LDL 10 
cholesterol), II) higher risk for complex and severe CAD, and III) male gender.  11 
Coexpedia67, an open tool for exploring biomedical hypotheses via coexpression analyses, 12 
revealed in 467 different studies by gene set analysis the most relevant biological correlates of 13 
MAFF to be LDLR mediated cholesterol biosynthetic process (p=1.40e-23), negative regulation 14 
of apoptotic process (p=8.47e-7), and inflammatory response (p=3.28e-5). Further, gene set 15 
analysis of disease ontology highlighted several CAD relevant traits and risk factors. MAFF 16 
expression was associated with arthritis (p=1.86e-20), ischemia (p=7.76e-12), myocardial 17 
infarction (p=1.37e-11), atherosclerosis (p=4.14e-10) and coronary heart disease (p=1.74e-8). 18 
On risk factor level hypertension (p=3.15e-12), obesity (p=9.38e-12), diabetes mellitus 19 
(p=1.44e-9), kidney disease (p=9.49e-9) and hypercholesterolemia (p=7.32e-5) showed 20 
significant association with MAFF. 21 
 22 




To confirm the role of MAFF orchestrating the predicted regulatory liver network of CAD genes 1 
Hep3b and AML12 were studied representing human and mouse hepatocyte cell lines, 2 
respectively. siRNA-knockdown (KD) of MAFF in human cells and Maff in mouse cells 3 
showed consistent, significant reductions of the LDLR/Ldlr expression (p<0.001) (Figure 4a+b) 4 
(Expanded Methods), as well as consistent and significant perturbations of other neighbouring 5 
genes. MAFF/Maff-KD caused significant upregulation of EPHA2/Epha2, GDF15/Gdf15 and 6 
TNFAIP3/Tnfaip3, in contrast to LDLR/Ldlr downregulation in both species. These results are 7 
in line with the predictions of the Bayesian networks in that these genes are downstream of 8 
MAFF/Maff (Supplemental Figure 2).  9 
Knockdown of MAFF/Maff did not perturb expression levels of Trib1 in AML12 cells and only 10 
slightly decreased expression values in human Hep3b cells. By contrast, siRNA knockdown of 11 
TRIB1/Trib1 led to decreased levels of MAFF/Maff in both cell lines (p<0.05), suggesting that 12 
the known CAD risk gene TRIB1 might be upstream acting as a regulator of MAFF/Maff 13 
expression levels, which was consistent with the Bayesian modeling.  14 
Further, the effect of Maff overexpression was investigated using plasmid DNA transfection in 15 
mouse AML12 cells and revealed a significant upregulation of the Ldlr expression (p=0.002) 16 
(Figure 4c). Based on these silencing and overexpression experiments in the absence of 17 
inflammatory stimuli, Maff and Ldlr expression was found to be positively correlated in vitro. 18 
 19 
Ldlr reduction in Maff-/- mouse models 20 
To explore in vivo the effects of MAFF on the expression levels of Ldlr, an inbred Maff-/- mouse 21 
model on C57BL/6-background was employed. Homozygous null mice are viable and fertile 22 




(WT) mice, all fed with chow diet, were collected. Expectedly, circulating cholesterol levels 1 
were low in mice lacking a pro-atherosclerotic background (e.g. Apoe-/-, Ldlr-/-). Maff-/-  mice 2 
showed no significant differences on serum cholesterol levels compared to WT mice. 3 
Significant decrease of Ldlr expression levels in Maff-/- mice was observed compared to WT 4 
mice (p=0.028) (Figure 4d) and lower amounts of Ldlr protein were confirmed by Western blot 5 
analysis in Maff-/- compared to WT mice (p=0.010). This is in line with the in vitro findings. 6 
There was no significant difference between the groups and heterozygous Maff mice.  7 
 8 
Context specific influence on MAFF and LDLR in the presence of LPS stimulation 9 
Maff has been described to be a context specific transcription factor.64 Pro-inflammatory 10 
lipopolysaccharide (LPS) was used intraperitoneally as a strong inductor of acute systemic 11 
inflammation in male Maff WT and knockout (KO) mice. A significant induction of Maff 12 
expression levels (p<0.001) was detected in WT animals six hours after LPS treatment. Maff 13 
mRNA was not detectable in Maff-/- mice. In addition to changes in Maff levels, there was a 14 
significant decrease of Ldlr expression levels in the WT group (p<0.001), but no significant 15 
change in Maff-/- mice, suggesting that Maff and its network are sensitive to inflammatory 16 
processes and that Maff is involved in inflammation induced suppression of Ldlr (Figure 4e-f). 17 
Circulating Ldl/Vldl cholesterol levels were non-significantly elevated in Maff WT mice 18 
compared to LPS treated Maff WT mice (66.1mg/dl vs. 61.4mg/dl, p=0.24) six hours after LPS 19 
injection. Further, expression of the pro-inflammatory cytokine Tnfa was assessed in Maff WT 20 
and Maff-/- mice with and without LPS treatment. Tnfa expression was significantly 21 
upregulated in Maff WT and Maff-/- mice after LPS stimulation (p<0.001). However, 22 
comparing Tnfa expression between both groups 6 hours after LPS stimulation, upregulation of 23 




4g). Under inflammatory conditions – using LPS stimulation – Maff and Ldlr expression was 1 
found to be inversely correlated in Maff WT mice.  2 
Identification of the regulatory MAFF binding site  3 
Next, the regulatory role of MAFF as a transcription factor was investigated in the network. 4 
Potential binding sites of MAFF were assessed using Chromatin-Immuno-Precipitation-DNA-5 
Sequencing (ChIP-Seq) data on human HepG2 cells as studied in the ENCODE project.68 6 
Computational analysis revealed a Leucine-Zipper binding motif to be enriched in binding 7 
elements of gene members of the MAFF network (20 of 24 genes, Fisher’s exact test, fold 8 
change=4.03, p=3.2e-34). Moreover, multiple MAFF binding sites were identified in the LDLR 9 
gene, including the promoter region (Figure 5). These results suggest that MAFF has the 10 
potential to bind to the promoter regions of the network member genes and regulate their 11 
expression. 12 
 13 
MAFF binding partners in homeostasis and inflammation 14 
To further elucidate the role of MAFF/Maff and its binding partners in homeostasis and 15 
inflammation Chromatin Immunoprecipitation followed by mass spectrometry (ChIP-MS) was 16 
performed in Hep3b and AML12 liver cells. Both cell lines were treated with either vehicle 17 
PBS or LPS (10ng/ml) for 48h with and without MAFF/Maff siRNA knockdown.  18 
MAFF/Maff siRNA knockdown and LPS stimulation identified BACH1/Bach1 as relevant 19 
transcriptional interaction partner of MAFF/Maff (Figure 6). Specifically, LPS induction 20 
determined BACH1/Bach1 as a robust MAFF/Maff interactor in both cell lines. On expression 21 
level, LPS stimulation led to a significant increase of BACH1/Bach1 expression in human 22 




7a+b). BACH1/Bach1 is a known repressor of the MARE – also known as stress-responsive 1 
element – and downregulates transcription (Figure 8).69 Of note, BACH1 is a human CAD 2 
GWAS candidate gene and the underlying mechanism of how BACH1 contributes to CAD is 3 
unclear.70 4 
Also the heterochromatin markers Trim28 (Kap1) and Cbx3, as well as the RNA related factors 5 
Dhx40, Srrm1 and Srsf2/5 were enriched in Maff ChIP-MS of LPS stimulated AML12 mouse 6 
liver cells. A clear reduction of the enrichment signal in response to Maff knockdown indicated 7 
that these proteins are specific Maff interactors (Figure 6c+d). Maff interactors and their 8 
individual enrichment patterns under different conditions are summarised after normalisation 9 
in Figure 7c.  10 
Further, it was studied if activating transcription factors bind with MAFF/Maff under basal 11 
conditions and in the presence of LPS stimulation in both cell lines. No enrichment of activating 12 
transcription factors was identified comparing both conditions. 13 
 14 
Verification of MAFF-BACH1 heterodimers binding at the LDLR promotor 15 
Based on the findings of the ChIP-MS approach in human Hep3b cells, human ChIP-Seq data 16 
was used to validate the binding capacities of the MAFF heterodimerisation partners at the 17 
LDLR promoter. Three dimensional structures of heterodimers were modeled (Expanded 18 
Methods) and confirmed the preferred binding of the MAFF-BACH1 complex at the LDLR 19 





Gene regulatory network modelling based on hundreds of genes known to affect atherosclerosis 2 
retrieved a dense liver network highly enriched for mouse atherosclerosis and human CAD 3 
GWAS candidate genes. Notably, the network – centered at the transcription factor MAFF – 4 
contains LDLR and inflammatory genes, which are all implicated to play causal roles in 5 
coronary artery disease. Prediction by Bayesian models and experimental studies clarified the 6 
hierarchical order and regulatory direction of the genes within the network as well as the central 7 
role of MAFF as a regulating element.  8 
Under non-inflammatory conditions a positive correlation between MAFF and LDLR 9 
expression in vitro and in vivo was identified, whereas inflammatory conditions led to inverse 10 
correlation between MAFF and LDLR expression. Most importantly, after acute induction of 11 
systemic inflammation via LPS stimulation, we observed that binding of MAFF-BACH1 12 
heterodimers at the MARE in the LDLR promoter region significantly downregulated LDLR 13 
expression (Figure 8).  14 
BACH1 resides at a genome-wide significant CAD GWAS locus and the underlying mechanism 15 
how BACH1 contributes to CAD progression is hitherto unknown.70 Based on pathway analyses 16 
BACH1 has been described to be involved in vascular remodeling, proliferation and 17 
transcriptional regulation.71 We speculate that BACH1 promotes atherosclerosis based on the 18 
downregulation of the LDLR via MAFF. 19 
The transcriptome studies in mouse models and human samples as well as in vitro and in vivo 20 
MAFF perturbation experiments provided evidence supporting a context-specific role of MAFF 21 
in the regulation of LDLR as well as other genes. In vivo data from STARNET, including liver 22 
tissue samples from a large set of CAD patients undergoing bypass surgery showed a significant 23 




expression values of MAFF were found in men and were significantly correlated with more 1 
complex and severe coronary artery lesions as measured by the Syntax Score I. Likewise, a 2 
positive correlation between Maff and Ldlr was found in mice on chow and high-fat diets in 3 
HMDP. In mice with transgenic expression of human APOE-Leiden and CETP, which display 4 
a significant increase of inflammatory cytokines, showed in contrast a significant inverse 5 
correlation between Maff and the Ldlr. These results support a context-specific relationship 6 
between the expression of Maff and Ldlr. 7 
Substantial convergence of tissue-specific regulatory mechanisms was observed in the 8 
MAFF/Maff liver specific network between human and mouse. The finding that knockdown of 9 
Maff in vitro in a mouse hepatocyte cell line led to reduced expression of the Ldlr was validated 10 
in a human in vitro model, highlighting similar interaction patterns between MAFF and LDLR 11 
in human and mouse. Besides LDLR, the other experimentally examined neighbouring genes 12 
within the MAFF network (EPHA2, GDF15, TNFAIP3, and TRIB1) also showed convergent 13 
regulation in human and mouse liver cell lines. The in vivo data in Maff knockout mice strongly 14 
supported this assumption. Additionally, the presence of MAFF binding motifs in the LDLR 15 
gene region and 19 out of the overall 24 additional predicted neighbouring genes using human 16 
ChIP-Seq data were identified. However, under baseline conditions it was not achievable to 17 
identify the molecular partners effecting LDLR/Ldlr downregulation following MAFF/Maff 18 
silencing, in contrast to inflammatory conditions. Nevertheless, Maff overexpression in AML12 19 
cells led to significant upregulation of the Ldlr under non-inflammatory conditions.  20 
MAFF was also found to be sensitive to environmental stimuli (e.g. high-fat diet, inflammation). 21 
Treatment with lipopolysaccharides markedly increased inflammatory cytokine levels in the 22 
liver of wildtype mice, as measured by Il1b, Il6 and Tnfa levels and led to an excessive 23 




elevated inflammatory mediators and inverse correlation of Maff and Ldlr expression levels has 1 
been identified in the HMDP in mice with transgenic implementation of human APOE-Leiden 2 
and CETP.  This is in line with findings in the literature, that cholesterol accumulation in cells 3 
of genetically modified mouse models triggers the inflammasome and results in elevated release 4 
of inflammatory mediators such as Il1b, Il6 and Tnfa.72  5 
Indeed, inflammation and perturbation of cholesterol levels coincide in several human 6 
conditions, including rheumatoid arthritis (RA), which goes along with an increased risk of 7 
cardiovascular events.73-77 Recently, Fernández-Ortiz and colleagues studied lipid metabolism 8 
in different stages of RA disease activity and observed that total cholesterol, LDL cholesterol 9 
and oxidized LDL cholesterol were slightly elevated in the low disease activity group, whereas 10 
high disease activity individuals showed distinct reduction of total cholesterol, HDL cholesterol 11 
and LDL cholesterol along a drastic increase of pro-atherosclerotic oxidized LDL cholesterol.78 12 
These alterations are mirrored by a gene set analysis of disease ontology67 focused on MAFF 13 
expression revealing its association with arthritis, LDLR expression, atherosclerosis and 14 
myocardial infarction risk. Thus, our offer an explanation on that MAFF could be a link between 15 
inflammation, lipid and lipoprotein metabolism and cardiovascular disease. 16 
Limitations 17 
Bioinformatics analyses on key drivers of liver gene expression may be further enriched in the 18 
future as the numbers of loci showing significant signals in human CAD GWAS and mouse 19 
candidate genes will increase within the next years. However, our previous network modeling 20 
of CAD GWAS loci demonstrated that network predictions are relatively insensitive to changes 21 
in the number of loci included, supporting the robustness of the overall patterns of disease 22 
pathways and networks.79 In this study, a MAFF centered regulatory network was revealed 23 




MAFF on downstream targets, and its regulation by inflammatory mediators. The molecular 1 
mechanisms affecting MAFF expression as well as MAFF downstream targets remain 2 
inadequately understood. Specifically, the molecular partners of MAFF executing 3 
transcriptional activation of LDLR under non-inflammatory conditions remain to be elusive. By 4 
contrast, BACH1 was identified to physically interact with MAFF in the presence of LPS 5 
stimulation. While we provided multiple layers of evidence placing MAFF in the center of a 6 
top ranked liver-specific key-driver network linking lipid metabolism and inflammation, further 7 
investigations should aim to identify potential mechanisms relevant for cardiovascular risk via 8 
regulation of MAFF, LDLR and downstream pathways. Of specific interest would be the 9 
elucidation of the molecular model explaining MAFF-related LDLR induction and subsequent 10 
atheroprotective effects. In this respect our findings may be a starting point for a better 11 
elucidation of interactions between inflammatory processes, hypercholesterolemia and CAD 12 
risk.  13 
In conclusion 14 
The transcription factor MAFF is the key driver of a liver specific network which includes a 15 
large number of genes known to affect atherosclerosis in mouse and human. Depending on the 16 
underlying context (non-inflammatory vs. inflammatory) MAFF is able to mediate activation 17 
or repression of gene expression.80, 81 Under non-inflammatory conditions MAFF appears to 18 
induce LDLR expression. In the presence of LPS stimulation, heterodimerisation of MAFF with 19 
the CAD GWAS candidate and transcriptional regulator BACH182 binding at the MARE in the 20 
promoter region of the LDLR led to downregulation of LDLR expression. It appears that both, 21 
the degree of inflammation (none vs. excessive) and expression values of MAFF modulate these 22 




connection between MAFF and the LDLR and also revealed significant changes in this 1 
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Figures  1 
 2 
Figure 1. Study workflow: Human and mouse atherosclerosis candidate genes were used to first model 3 
liver specific regulatory networks and second decipher key driver genes of gene regulatory networks in 4 
both species. Prediction of bioinformatics modeling was validated in human and mouse genetic studies 5 
as well as in in vitro and in vivo experiments. CAD: Coronary artery disease; GWAS: Genome wide 6 





Figure 2. Liver specific regulatory subnetworks and their key driver genes. The key driver analysis was 2 
performed on human and mouse networks respectively and the architecture of the illustrated network is 3 
based on both, mouse and human data. Key drivers are depicted as the largest nodes in the networks. 4 
All genes highlighted in solid green have already been studied to have a significant effect on 5 
atherosclerosis in genetically engineered mouse models. Human CAD GWAS candidate genes are 6 
highlighted in magenta. Key driver genes in grey need to be validated. Genes with both colors have an 7 
effect on atherosclerosis/CAD in human and mouse. Lower right: The MAFF network is the top ranked 8 
key driver gene network based on mouse data and closely connected to other human key driver 9 
subnetworks. Directionality between genes was based on the consensus of directional predictions from 10 
Bayesian networks constructed from different datasets, with the directionality predicted by the majority 11 
of studies shown. Red arrows indicate genes that are predicted to regulate MAFF, whereas green arrows 12 
indicate genes that are predicted to be regulated by the transcription factor MAFF. CAD: coronary artery 13 
disease; GWAS: Genome wide association study; Human KD: Human key driver gene; Mouse KD: 14 





Figure 3. Correlation of expression levels of MAFF in human liver samples from the Stockholm-Tartu 2 
Atherosclerosis Reverse Network Engineering Task (STARNET) with A: LDLR and B: Sex. ** 3 
indicates p<0.01. LDLR: low-density lipoprotein receptor; MAFF: v-Maf avian musculoaponeurotic 4 





Figure 4. A: In vitro results of Ldlr expression after siRNA-knockdown of Maff compared to controls 2 
(vehicle) in mouse AML12 liver cells. B: In vitro results of LDLR expression after siRNA-knockdown 3 
of MAFF compared to controls (vehicle) in human Hep3b liver cells. C: In vitro results of Ldlr 4 
expression cells after Maff overexpression compared to controls (vehicle) in mouse AML12. D: In vivo 5 
results of Ldlr expression in Maff-/- mice compared to Maff+/- and WT mice. E: In vivo results of Maff 6 
expression in Maff WT mice 6 hours after LPS stimulation compared to controls (vehicle). F: In vivo 7 
results of Ldlr expression in Maff WT mice 6 hours after LPS stimulation compared to controls (vehicle). 8 
G: In vivo results of Tnfa expression in Maff WT and Maff-/- mice 6 hours after LPS stimulation 9 
compared to controls (vehicle). *** indicates p<0.001, ** indicates p<0.01, * indicates p<0.05, ns 10 
indicates non-significant. Bonferroni correction was applied for multiple comparison. Ctrl: control 11 
group; KD: knockdown; LDLR: low-density lipoprotein receptor; LPS: lipopolysaccharide; MAFF: v-12 




   1 
Figure 5. A: ChIP-seq data of human HepG2 cells supports potential binding of MAFF to genes in the 2 
MAFF subnetwork. Green edges indicate a binding motif was shared in the selected network genes, 3 
whereas red edges indicate that no known shared binding motif was found in the particular network 4 
genes. A matching binding motif was found in 20 out of 24 predicted interaction partners of MAFF. B: 5 
The matching motif among the MAFF network genes, which agrees with the previously known MAFF 6 
binding motif. The matching motif was identified using publically available ChIP-Seq data of the MAFF 7 
gene in human HepG2 cells from ENCODE. The height of the letter represents the frequency of the 8 
observed nucleotide in that position. C: Presence of the MAFF binding motif (small boxes below) 9 





Figure 6. Volcano plot of the p-values (y-axis) vs. the log2 protein abundance differences (x-axis) of 2 
Maff binding partners in AML12 cells identified by ChIP-MS under (A) homeostatic conditions, (B) 3 
after Maff siRNA knockdown (which led to a 91% decrease on protein level), (C) LPS stimulation and 4 
(D) Maff siRNA knockdown in combination with LPS stimulation. Significant Maff interaction partners 5 
were highlighted in blue. Enrichment of binding partners is provided as fold difference compared to 6 
negative control (IgG) in panel A and C and compared to control (Maff WT) after siRNA knockdown 7 





Figure 7. LPS stimulation led to a significant increase of BACH1/Bach1 expression in mouse AML12 2 
cells (A) and human Hep3b cells (B) compared to controls (vehicle). (C) The heat map of z-scored Maff 3 
ChIP-MS visualises LFQ intensities of selected Maff interactors in extracts from AML12 cells under 4 
homeostatic conditions (Ctrl), LPS stimulation (Ctrl+LPS), after Maff siRNA knockdown (siRNA) and 5 
after Maff siRNA knockdown in combination with LPS stimulation (siRNA+LPS). Provided are 6 





Figure 8. The role of the transcription factor MAFF in activation or repression of the LDLR is based on 2 
heterodimerisation partners and environmental conditions. MAFF heterodimers bind at the MAF 3 
recognition element (MARE) of the LDLR promoter and execute regulation of the LDLR. Under basal 4 
conditions 1) MAFF knockdown/knockout led to reduced LDLR expression, 2) elevated MAFF 5 
expression was correlated with higher expression of LDLR in a human CAD cohort (STARNET) and 6 
in wildtype mice of the hybrid mouse diversity panel (HMDP), 3) Overexpression of Maff using plasmid 7 
DNA transfection led to increased Ldlr expression in vitro. In the presence of LPS stimulation MAFF-8 
BACH1 heterodimers result in downregulation of the LDLR in vivo. HMDP mice on atherogenic 9 
background (transgenic expression of human APOE-Leiden and cholesteryl ester transfer protein 10 
(CETP)) showed increased inflammation and revealed that elevated Maff expression correlates with 11 
lower Ldlr expression. BACH1: BTB domain and CNC Homolog 1; MAFF: v-Maf avian 12 
musculoaponeurotic fibrosarcoma oncogene homolog F; MARE: Maf recognition element; LDLR: low-13 




Table 1. Listed are the top 10 key driver genes detected in human and mouse liver networks based on 1 
the bioinformatics approach. Several genes have already been studied and confirmed with regard to 2 















Maff no 25 11 1.50E-05 19.08 
Il1b yes 27 11 1.50E-05 19.08 
Ccl7 yes 34 12 1.17E-05 16.53 
Atf3 yes 50 15 3.89E-06 14.05 
Cxcl10 yes 46 13 1.26E-05 13.23 
Egr2 no 50 14 7.79E-06 13.11 
Igsf6 no 66 18 1.49E-06 12.77 
Ltb no 44 12 2.45E-05 12.77 
Itgal no 52 14 8.81E-06 12.61 
Tlr2 yes 57 15 5.90E-06 12.32 
Human 
ALDH2 yes 19 4 1.10E-04 31.29 
IL15RA no 20 4 1.50E-04 29.72 
ZNF467 no 22 4 2.70E-04 27.02 
NGRN no 32 5 1.87E-07 23.22 
LOXL2 no 28 4 1.15E-03 21.23 
ABCG8 yes 30 4 1.73E-03 19.82 
ABCG5 yes 33 4 3.00E-03 18.01 
SERPINE1 no 34 4 3.55E-03 17.48 
COL6A3 no 69 6 1.22E-07 12.92 




Supplemental Materials Appendix 1 
Supplemental Table 1. List of 244 human CAD candidate genes based on annotations of 169 known 2 
significant and suggestive human CAD GWAS loci. 3 
Supplemental Table 2. List of 827 mouse atherosclerosis genes as defined by a significant effect on 4 
atherosclerotic lesion size or composition when perturbed in a mouse model. 5 
Supplemental Table 3. Correlation analysis of network genes in HMDP and STARNET based on 6 
Pearson correlation coefficient.  7 
Supplemental Figure 1. Comparison of pair-wise correlations among all Maff network genes according 8 
to their expression values in three HMDP populations. Large and bright circles represent strong 9 
correlations.  A: Mice on chow diet. B: Mice on high-fat diet. C: Mice on high-fat diet with transgenic 10 
implementation of human APOE-Leiden and CETP.  11 
Supplemental Figure 2. A: In vitro results of MAFF neighbour gene expression after siRNA 12 
knockdown of MAFF in human Hep3b liver cells and B: In vitro results of Maff neighbour gene 13 
expression after siRNA knockdown of Maff in mouse AML12 liver cells. * indicates p<0.05, ** 14 
indicates p<0.01, *** indicates p<0.001. Ctrl: control group; KD: knockdown; LDLR: low-density 15 
lipoprotein receptor; MAFF: v-Maf avian musculoaponeurotic fibrosarcoma oncogene homolog F.  16 
Supplemental Figure 3. Three-dimensional binding of the heterodimerised transcription factor MAFF 17 
(blue) and the transcriptional repressor BACH1 (red) at the MARE of the LDLR promoter in the presence 18 
of LPS stimulation. BACH1: BTB domain and CNC Homolog 1; MAFF: v-Maf avian 19 
musculoaponeurotic fibrosarcoma oncogene homolog F; MARE: Maf recognition element; LDLR: low-20 




Supplemental Table 3. Correlation between Maff/MAFF and its network genes under different conditions. HMDP mice on chow diet, high-fat diet and with 1 
transgenic implementation of human APOE-Leiden and CETP (left). On the right, human data from the STARNET cohort. 2 
  Mouse data (HMDP) Human data    













R p-value Gene 
Arid5b 0.10 1.30E-01 0.08 2.31E-01 0.13 5.87E-02 -0.12 7.33E-02 0.09 3.79E-01 0.04 3.05E-01 ARID5B 
Atf3 0.06 3.24E-01 0.17 1.70E-02 0.09 1.78E-01 0.26 7.31E-05 0.37 1.58E-04 0.66 2.26E-68 ATF3 
Clcf1 -0.17 6.67E-03 0.01 8.50E-01 -0.01 8.39E-01 0.26 7.66E-05 0.34 4.35E-04 0.43 1.54E-26 CLCF1 
Crem -0.10 1.01E-01 -0.27 1.07E-04 -0.35 4.89E-08 -0.22 8.67E-04 -0.21 3.29E-02 0.35 2.97E-17 CREM 
Dusp5 n/a n/a n/a n/a n/a n/a 0.09 2.00E-01 0.31 1.57E-03 0.62 5.74E-59 DUSP5 
Epha2 0.03 6.44E-01 -0.08 2.33E-01 -0.08 2.23E-01 -0.06 3.89E-01 -0.07 4.92E-01 0.62 2.99E-59 EPHA2 
Fosl2 0.01 8.68E-01 0.00 9.51E-01 -0.11 8.88E-02 0.30 5.72E-06 0.37 1.36E-04 0.54 3.54E-42 FOSL2 
Foxp1 -0.15 1.56E-02 -0.07 3.05E-01 -0.23 5.95E-04 0.26 7.38E-05 0.33 6.36E-04 -0.03 4.43E-01 FOXP1 
Gdf15 0.31 4.14E-07 0.17 1.74E-02 0.16 1.46E-02 0.09 1.91E-01 0.31 1.54E-03 0.57 2.88E-48 GDF15 
Ldlr 0.30 9.88E-07 0.35 1.78E-07 0.30 2.90E-06 -0.27 4.65E-05 -0.19 4.98E-02 0.57 4.70E-49 LDLR 
Mcl1 0.42 5.30E-12 0.27 9.79E-05 0.25 1.62E-04 0.37 1.35E-08 0.35 3.82E-04 0.47 4.86E-31 MCL1 
Nav2 -0.14 2.50E-02 -0.16 2.16E-02 0.03 7.06E-01 -0.38 9.23E-09 -0.26 7.24E-03 0.31 2.03E-13 NAV2 
Nr4a3 -0.08 2.00E-01 -0.06 3.61E-01 -0.14 3.38E-02 0.22 1.10E-03 0.37 1.44E-04 0.35 5.81E-17 NR4A3 
Phlda1 0.16 1.21E-02 -0.07 3.07E-01 0.00 9.53E-01 -0.09 1.83E-01 -0.03 7.83E-01 0.48 8.69E-33 PHLDA1 
Ppp1r15a 0.00 9.70E-01 0.10 1.56E-01 0.26 7.86E-05 0.32 1.91E-06 0.28 4.25E-03 0.67 2.05E-72 PPP1R15A 
Serpine1 0.17 7.92E-03 0.42 2.01E-10 0.54 1.40E-18 0.53 4.63E-17 0.37 1.57E-04 0.43 1.54E-26 SERPINE1 
Slc20a1 0.23 1.73E-04 0.40 3.28E-09 0.49 5.78E-15 0.50 1.44E-15 0.24 1.59E-02 0.41 2.66E-23 SLC20A1 
Tgfbi -0.16 1.27E-02 0.02 7.54E-01 0.09 1.55E-01 0.31 3.97E-06 0.35 2.54E-04 0.31 1.22E-13 TGFBI 
Tnfaip3 n/a n/a n/a n/a n/a n/a 0.32 1.81E-06 0.27 6.00E-03 0.46 6.02E-30 TNFAIP3 
Tnfrsf12a -0.18 3.11E-03 0.13 5.55E-02 0.19 3.79E-03 0.30 4.52E-06 0.27 6.26E-03 0.62 5.74E-59 TNFRSF12A 
Trib1 0.20 1.50E-03 0.31 5.93E-06 0.37 1.03E-08 0.11 8.98E-02 0.08 4.13E-01 0.4 3.49E-22 TRIB1 
Tsc22d1 -0.06 3.35E-01 -0.29 2.90E-05 -0.11 9.25E-02 -0.18 6.88E-03 -0.26 7.57E-03 0.48 8.35E-33 TSC22D1 
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